GenPharmaChain earns $500000

GenPharmaChain Secures $500,000 in Pre-Seed Funding to Revolutionize AI-Driven Drug Development

GenPharmaChain, a pioneering blockchain-based AI pharmaceutical research platform, has successfully secured $500,000 in its pre-seed funding round. The investment was led by M2M Capital (@M2MCapital), FNODE Venture (@FNodeVenture), Pharma Lab (@Pharmalab700), and Avatia Pharmaceutical Company, with strategic support from Google, AWS and several angel investors from top-tier Web3 exchanges and VC。

Through its decentralized network, GenPharmaChain incentivizes developers to refine AI-driven pharmaceutical models. Scientists and individuals can integrate AI modules to simulate drug interactions, facilitating groundbreaking biomedical research. Early investors have the opportunity to support high-potential AI models, with increased rewards when these models contribute to successful drug pipelines.

GenPharmaChain is redefining pharmaceutical research with its Decentralized Scientific AI (DeSAI) modeling framework. By aggregating AI-driven drug development models and enabling scientists to combine modular AI units into comprehensive drug pipelines, the platform enhances both AI model efficiency and pharmaceutical value chains.With a robust database of over 80,000 protein records, 4,000 drug profiles, and 98 million data points, GenPharmaChain ensures high accuracy in AI model validation. Key innovations include:

AI-ADMET Testing – Predicting small molecule absorption, metabolism, and toxicity through molecular structure analysis.

AI-Powered Protein Structure Prediction – Identifying drug targets and accelerating drug discovery.